February 27th Options Now Available For Moderna (MRNA)

At MRNA's current price of $35.20, Stock Options Channel highlights two option strategies: selling the $30 put (bid $1.04) would set an effective purchase basis of $28.96 and is ~15% out-of-the-money with a modeled 74% chance to expire worthless, implying a 3.47% return (25.31% annualized). Alternatively, selling a $40 covered call (bid $1.46) from current stock ownership would cap sale at $40 and deliver a 17.78% return to that strike by the Feb 27 expiration, with a 62% chance to expire worthless and a 4.15% immediate yield (30.28% annualized). Implied volatility is 91% for the put and 70% for the call versus a trailing 12‑month volatility of 67%; Stock Options Channel will track the contract odds and histories on its site.

Analysis

Market structure: The option market is signaling asymmetry — puts trade with IV ~91% vs calls 70% against 67% realized vol, implying elevated demand for downside protection and a put skew. Short-vol sellers and cash-rich investors able to carry assignment (or deploy collateral) are the immediate winners (collecting 3.47% cash yield to Feb27); directional buyers of long-dated upside are disadvantaged by expensive near-term premium. Cross-asset: a negative idiosyncratic shock to MRNA would likely drive small risk-off flows into Treasuries and USD; a positive surprise can compress equity vols and draw carry out of fixed income.

Risk assessment: Tail risks include clinical/regulatory setbacks or unexpected liability events that could push shares well below the $30 strike (low-probability but >10% single-day gap risk for biotech). Time horizons matter: days–weeks (option theta decay and Feb27 expiries dominate P/L), months (trial readouts/earnings), years (product commercialization). Hidden dependencies: revenue sensitivity to vaccine demand and partner royalties; IV skew may spike ahead of company-specific news even without fundamental deterioration. Key catalysts: Feb27 expiration, upcoming earnings/clinical calendar, and macro volatility (Fed/PPI) in next 30–90 days.

Trade implications: Tactical income trade — sell-to-open MRNA Feb27 $30 puts (collect $1.04) as defined-risk capital-efficient exposure if willing to buy at $28.96; alternative is buy shares at $35.20 and sell $40 Feb27 calls to cap upside for a 17.8% gross return to $40. Volatility strategy: favor short-dated credit structures (bull put spreads or covered calls) rather than naked short-deltas given 91% put IV and 67% realized vol; size ≤2% NAV per strategy and use protective long puts or spreads. Entry/exit: initiate before expected clinical/earnings headlines if IV is stable; trim/close if IV >120% or stock gaps >12% intraday.

Contrarian angles: Consensus overlooks that >60% odds of calls expiring worthless imply potential IV compression absent news — sellers may be overcompensated if no catalyst arrives, creating edge for short-dated premium sellers. Conversely, buying stock and selling calls underprices large positive binary re‑rating risk; if management announces stronger guidance, capped covered-call holders will be forced to roll. Historical parallels: biotech post-readout IV collapses (2019–2021) often produced 25–40% realized moves; be wary of assignment risk and liquidity gaps around event dates.

Key Decisions for Investors

• Sell-to-open MRNA Feb 27 $30 put (bid ~$1.04) sized to 1.0% of portfolio NAV (one contract ≈100 shares per $35k NAV) to collect premium and set a net purchase basis at $28.96; place a mental buy-if-assigned plan and close position if MRNA < $27.50 or IV rises above 120% (cut loss at 20% of notional).
• Buy MRNA equity up to 1–2% NAV at current levels ($35.20) and sell-to-open Feb 27 $40 call (collect ~$1.46) as a covered-call for a capped gross return of ~17.8% to $40; set a hard stop-loss at –18% from purchase and roll calls outward if price >$40 to retain shares into longer-dated catalysts.
• If exposure to implied-vol decay desired, implement limited-risk bull put spreads: sell Feb 27 $30 put and buy Feb 27 $25 put (size 0.5% NAV) to collect a net credit while capping downside; unwind if spread mark moves against you by 50% or underlying < $29.
• Relative-value hedge: for idiosyncratic long exposure, pair long MRNA (0.5–1% NAV) with a 0.5% short position in XBI (SPDR S&P Biotech ETF) to reduce sector beta ahead of binary events; unwind post-catalyst or if MRNA outperforms XBI by >15%.